Gene Transfer Clinical Trial for Krabbe Disease (RESKUE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04693598 |
Recruitment Status :
Not yet recruiting
First Posted : January 5, 2021
Last Update Posted : January 7, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Krabbe Disease | Biological: FBX-101 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 6 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Dose escalation study from a low dose to a high dose following safety review |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE) |
Estimated Study Start Date : | January 2021 |
Estimated Primary Completion Date : | April 2023 |
Estimated Study Completion Date : | April 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)
Participants will receive a single infusion at the lower dose (N=3 participants)
|
Biological: FBX-101
A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Other Name: AAVrh.10-hGALC |
Experimental: Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)
Participants will receive a single infusion at the higher dose (N=3 participants)
|
Biological: FBX-101
A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Other Name: AAVrh.10-hGALC |
- Safety as assessed by less than 3 incidents of organ specific AEs/SAEs at Grade 3 or higher based on CTCAE criteria attributed to the AAV administration. [ Time Frame: 12 months ]
- Safety as assessed by lack of HSCT engraftment. [ Time Frame: 12 months ]
- Efficacy as assessed by improvement of the probability to achieve independent sitting compared to patients receiving HSCT. [ Time Frame: 24 months ]
- Efficacy as assessed by improvement of gross motor function as measured by PDMS above a functional age equivalent of 12 months by 2 years post treatment. [ Time Frame: 24 months ]
- Exploratory endpoint as assessed by change in motor function as measured by GMFM88 and Adaptive Behavior compared to patients receiving HSCT only. [ Time Frame: 12 months and 24 months ]
- Exploratory endpoint as assessed by change in auditory brainstem responses compared to patients receiving HSCT only. [ Time Frame: 12 months and 24 months ]The brainstem auditory evoked responses are considered abnormal if either the interpeak latency of waves I to V is prolonged or if any of the obligate wave forms (I, III, or V) are missing.
- Exploratory endpoint as assessed by change in peripheral nerve conduction velocity compared to patients receiving HSCT only. [ Time Frame: 24 months ]
- Exploratory endpoint as assessed by change in brain MRI as measured by DTI compared to patients receiving HSCT only. [ Time Frame: 12 months and 24 months ]
- Exploratory endpoint as assessed by reduced diseased manifestation using biomarkers measuring reduction of psychosine levels and increase in GALC enzyme activities in the blood compared to patients receiving HSCT only. [ Time Frame: 12 months and 24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 12 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis of infantile Krabbe disease, characterized by the following criteria outlined below:
- Galactocerebrosidase (GALC) activity < 0.20 nmol/h/mg protein in leukocytes; AND AT LEAST ONE OF THE FOLLOWING:
- Elevated psychosine predictive of infantile disease ≥ 9.0 nmol/L; OR
- Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR); OR
- Two predicted pathogenic GALC mutations.
- Age at the time of screening: 1 day to 12 months
- Participant has been deemed eligible for treatment with HSCT (standard of care)
- Participant's parent or legal guardian consents to participate in the study and provides informed consent according to IRB guidelines prior to any study procedures being performed
- Parent(s) and/or legal guardian able to comply with the clinical protocol
- Participants must have a 4/6, 5/6 or 6/6 HLA matched UCB unit available with a pre-cryopreservation total nucleated cell dose of ≥ 5 x 10^7 cells/kg
-
Participant must have adequate organ function at time of screening as measured by:
- Creatinine ≤ 0.6 mg/dL and creatinine clearance ≥ 60 mL/min/1.73 m2 by nuclear medicine GFR
- Hepatic transaminases (ALT/AST) ≤ 2x age related upper limit of normal
- Ejection fraction of > 50% by echocardiogram or other appropriate study without evidence of pulmonary hypertension.
- Pulmonary evaluation testing demonstrating resting pulse oximeter > 92% on room air Coagulation tests within 110% of normal ranges for age. (PT/INR and PTT)
Exclusion Criteria:
- History of allogeneic HCT within 4 months
- History of prior treatment with a gene therapy product
- Presence of major congenital anomaly affecting the neurological system
- Presence of any neurocognitive deficit not attributable to Krabbe disease
- Premature birth at less than 35 weeks' gestation
- Active aspiration
- Signs of infection or disease from active cytomegalovirus, adenovirus or other viruses
- HIV positive
- Uncontrolled and progressive bacterial, viral, or fungal infection.
- Presence of any contraindication for MRI
- Use of any investigational product prior to study enrollment or current enrollment in another study that involves clinical interventions
- Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the PI, would preclude participation in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04693598
Contact: Medical Affairs | 3305549257 | medicalaffairs@forgebiologics.com |
United States, Pennsylvania | |
UPMC Children's Hospital of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15224 | |
Contact: Jodi Martin 412-692-6351 sausjl@upmc.edu | |
Principal Investigator: Jessie Barnum, MD | |
Sub-Investigator: Maria Escolar, MD |
Principal Investigator: | Jessie Barnum, MD | Div. of Blood & Marrow Transplantation & Cellular Therapies, UPMC Children's Hospital of Pittsburgh |
Responsible Party: | Forge Biologics, Inc |
ClinicalTrials.gov Identifier: | NCT04693598 |
Other Study ID Numbers: |
FBX-101 |
First Posted: | January 5, 2021 Key Record Dates |
Last Update Posted: | January 7, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan to share data |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lysosomal Storage Disorder Globoid Cell Leukodystrophy Leukodystrophy GALC |
Leukodystrophy, Globoid Cell Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Sphingolipidoses Lysosomal Storage Diseases, Nervous System |
Leukoencephalopathies Demyelinating Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |